Endocrinology and osteoporosis are tightly linked because bone is a hormone-controlled tissue. Osteoporosis develops when bone breakdown outpaces bone formation, and that balance is set largely by estrogen, testosterone, parathyroid hormone, vitamin D, thyroid hormone, and cortisol. Menopause is the most common hormonal driver, but conditions such as hyperparathyroidism, hyperthyroidism, hypogonadism, and Cushing’s syndrome (or long-term steroid tablets) cause a significant share of secondary osteoporosis. Recognizing these causes changes both the workup and the treatment.
This guide is written for clinicians and informed patients who want to understand the hormonal side of bone health. For a companion overview, see our article on the interplay of endocrinology and osteoporosis, and the wider osteoporosis guide.
Bone Remodeling: The Process Hormones Control
Bone is renewed throughout life by bone remodeling. Cells called osteoclasts dissolve small packets of old bone, and osteoblasts then lay down new matrix that mineralizes with calcium and phosphate. In young adults the two processes are matched, and peak bone mass is reached in the late twenties to early thirties.
Osteoporosis is the result of a mismatch: more resorption than formation, or both happening faster with a net loss at each cycle. The outcome is lower bone mass and weakened microarchitecture, so bones break with minimal trauma. Almost every hormonal influence on bone works by tipping this balance one way or the other.
Key Hormones and Their Effects on Bone
| Hormone | Normal effect on bone | How imbalance causes bone loss |
|---|---|---|
| Estrogen | Restrains osteoclast activity and lifespan | Deficiency after menopause or in amenorrhea accelerates resorption |
| Testosterone | Supports bone formation; partly converted to estrogen | Male hypogonadism or androgen-deprivation therapy speeds bone loss |
| Parathyroid hormone (PTH) | Maintains blood calcium; intermittent pulses build bone | Continuous excess (hyperparathyroidism) increases resorption, especially cortical bone |
| Vitamin D (calcitriol) | Increases calcium and phosphate absorption from the gut | Deficiency reduces mineralization and triggers secondary hyperparathyroidism |
| Thyroid hormone | Regulates the pace of remodeling | Excess, including over-replacement, shortens the remodeling cycle with net loss |
| Cortisol (glucocorticoids) | Normal levels needed for bone cell function | Excess suppresses osteoblasts and gut calcium absorption, raising fracture risk quickly |
Estrogen and menopause
Estrogen is the single most important hormone for female bone. In the years around menopause, the fall in estrogen releases the brake on osteoclasts, and bone loss is fastest in the first several years afterward. This explains why postmenopausal osteoporosis is the most common form of the disease.
Parathyroid hormone and vitamin D
PTH and vitamin D work as a pair to keep blood calcium stable. When calcium or vitamin D intake is low, PTH rises and draws calcium out of the skeleton. Primary hyperparathyroidism does the same through an overactive gland, usually a benign adenoma. Interestingly, PTH given as a once-daily injection has the opposite effect and stimulates new bone, which is the basis of anabolic therapy.
Endocrine Causes of Secondary Osteoporosis
Several endocrine disorders cause bone loss in their own right, and they are worth excluding in anyone with osteoporosis, especially men, premenopausal women, and people with unexpectedly low bone density for their age.
- Hypogonadism – low estrogen or testosterone from any cause, including early menopause, anorexia nervosa, pituitary disease, or hormone-suppressing cancer treatment.
- Primary hyperparathyroidism – suspected when blood calcium is high with an inappropriately normal or high PTH.
- Thyrotoxicosis – an overactive thyroid, or excessive thyroxine replacement that suppresses TSH.
- Cushing’s syndrome and glucocorticoid therapy – long-term oral steroids are the most common drug cause of osteoporosis, and fracture risk rises within months of starting them.
- Diabetes – both type 1 and type 2 diabetes are associated with higher fracture risk than bone density alone would predict.
- Vitamin D deficiency and malabsorption – including celiac disease and bariatric surgery.
Age, female sex, low body weight, smoking, heavy alcohol use, a family history of hip fracture, and a personal history of fragility fracture add to the hormonal risks.
Diagnosis: Imaging and Endocrine Testing
Bone density
Dual-energy X-ray absorptiometry (DXA) measures bone mineral density at the hip and spine. In postmenopausal women and men aged 50 and over, a T-score of -2.5 or lower confirms osteoporosis, and a score between -1.0 and -2.5 indicates low bone mass (osteopenia). A fragility fracture of the hip or spine supports the diagnosis regardless of the T-score. Fracture risk calculators such as FRAX combine density with clinical risk factors to guide treatment decisions.
Laboratory workup
A standard screen for secondary causes includes serum calcium, phosphate, alkaline phosphatase, creatinine, 25-hydroxyvitamin D, PTH, and TSH. Depending on the patient, clinicians add testosterone in men, a full blood count and protein electrophoresis to exclude myeloma, celiac serology, and tests for cortisol excess. Bone turnover markers, such as CTX and P1NP, can help monitor treatment response but do not diagnose osteoporosis.
Treatment Through an Endocrine Lens
Treatment has two parallel goals: correct any hormonal driver and reduce fracture risk directly. Treating hyperparathyroidism surgically, bringing thyroid hormone back into range, or reducing steroid doses where possible can all allow bone density to recover.
Foundations
Adequate calcium and vitamin D, weight-bearing and resistance exercise, stopping smoking, limiting alcohol, and fall prevention underpin every plan. Our article on the role of supplements in osteoporosis management covers dosing and when supplements help.
Medications
- Bisphosphonates (alendronate, risedronate, zoledronic acid) – slow osteoclast activity and are usually first-line.
- Denosumab – a monoclonal antibody that blocks RANKL, a signal osteoclasts need to form. It must not be stopped abruptly without follow-on therapy because of rebound bone loss.
- Raloxifene – a selective estrogen receptor modulator that mimics estrogen on bone, mainly protecting the spine.
- Menopausal hormone therapy – prevents bone loss and may suit younger postmenopausal women with menopausal symptoms, after weighing individual risks.
- Anabolic agents – teriparatide and abaloparatide (PTH-based) and romosozumab (which blocks sclerostin) build new bone and are reserved for very high fracture risk.
- Testosterone replacement – appropriate for men with confirmed hypogonadism, usually alongside a bone-specific drug.
Research continues into longer-lasting and combined approaches; our piece on current strategies and future directions in osteoporosis reviews where the field is heading.
Frequently Asked Questions
Why do endocrinologists treat osteoporosis?
Because osteoporosis is fundamentally a disorder of mineral and hormone regulation. Endocrinologists are trained to find and correct drivers such as hyperparathyroidism, thyroid excess, cortisol excess, and hypogonadism, and they manage complex cases that need anabolic therapy.
Can an overactive thyroid cause osteoporosis?
Yes. Excess thyroid hormone speeds up bone turnover so that more bone is lost with each cycle. This applies to thyroid over-replacement too, which is why TSH is checked in people on thyroxine who have low bone density.
Does vitamin D alone treat osteoporosis?
No. Correcting vitamin D deficiency is essential and prevents secondary hyperparathyroidism, but it does not by itself reverse established osteoporosis. It works as a foundation beneath specific bone medications.
Do men get hormone-related osteoporosis?
Yes. Low testosterone, steroid use, excess alcohol, and androgen-deprivation therapy for prostate cancer are common causes. Men with osteoporosis are more likely than women to have an identifiable secondary cause, so a thorough endocrine workup is standard.
Key Takeaways
- Bone strength depends on a hormone-regulated balance between osteoclasts and osteoblasts.
- Estrogen loss after menopause is the most common hormonal cause; PTH, vitamin D, thyroid, cortisol, and testosterone disorders cause secondary osteoporosis.
- DXA confirms the diagnosis, and a targeted endocrine blood panel uncovers treatable causes.
- Correcting the hormonal driver plus fracture-reducing medication gives the best outcome.
